Drug Profile
Bemnifosbuvir - Atea Pharmaceuticals
Alternative Names: AT-511-hemisulfate salt; AT-527 free base; AT‐527; RG-6422; RO 7496998Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Atea Pharmaceuticals
- Class Amines; Antivirals; Esters; Fluorinated hydrocarbons; Phosphorus compounds; Purine nucleotides; Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Hepatitis C
Most Recent Events
- 27 Mar 2024 Atea Pharmaceuticals completes enrolment in the phase III SUNRISE-3 trial for Covid-19 infections in Argentina, Brazil, Canada, Germany, India, Japan, Latvia, Mexico, Netherlands, Pakistan, Philippines, Romania, South Africa, Spain, Sweden, Tunisia, Turkey, United Kingdom and the US (PO) (EudraCT2022-003268-25) (NCT05629962)
- 09 Jan 2024 Efficacy and adverse events data from a phase II trial in Hepatitis C infection released by Atea Pharmaceuticals
- 13 Nov 2023 Pharmacodynamics data from a preclinical study in Hepatitis C released by Atea Pharmaceuticals